Clinical Trials in Egypt / NCT07642076
Recruiting
Phase 4
Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit
NCT07642076 · tracked via the Priya Life Science Egypt tracker
Condition(s) studied
Hepatic
Investigational drug(s) / intervention(s)
L Carnitine →Standard medical treatment
L Carnitine: L-Carnitine, a natural substance present in the body, is essential for energy metabolism in mammals. l-carnitine presents as a drug.
Standard medical treatment: Standard medical treatment for hepatic patient admitted to icu
Study summary
This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.
Eligibility
Inclusion Criteria:
* Age more than 18 years old
* male or female with confirmed liver disease admitted to intensive care unit, including:
* Acute-on-chronic liver failure (ACLF)
* Hepatic encephalopathy
* spontaneous bacterial peritonitis (SBP)
* variceal bleeding
* fulminant hepatitis
* Hepatorenal syndrome
* Ascites
* Etc
Exclusion Criteria:
* Age of less than 18 years old
* Pregnancy or Lactation
* patients have seizure
* patient on warfarin
Primary outcome measure(s)
- laboratory value: serum creatinine(SCr) — At ICU admission and at ICU discharge, an average of 7 days
- laboratory value: international normalized ratio — At ICU admission and at ICU discharge, an average of 7 days
- laboratory value: Blood urea nitrogen(BUN) — At ICU admission and at ICU discharge, an average of 7 days
- laboratory value: Albumin — At ICU admission and at ICU discharge, an average of 7 days
- laboratory value: Alanine aminotransferase(ALT) — At ICU admission and at ICU discharge, an average of 7 days
- laboratory value: Aspartate aminotransferase(AST) — At ICU admission and at ICU discharge, an average of 7 days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| National liver institute | Shibīn al Kawm | Egypt | Recruiting |
More Beni-Suef University trials in Egypt
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07642076 on ClinicalTrials.gov ↗ ← All trials in Egypt